Peer-Reviewed Publication
Int J Behav Med2025October 29, 2025Journal Article
Effect of Prevalent and Incident Comorbidity Diagnoses on Quit Attempts and Prescription of Smoking Cessation Medications, HIV Outpatient Study, 2007-2022.
Li Jun1, Carl Armon2, Alexander Ewing3, Jonathan Mahnken4, Ellen Tedaldi5, Frank Palella6, Richard M Novak7, Cynthia Firnhaber8,9, Stockton Mayer7, Andrea Wendrow7, Gina Simoncini10, Linda Battalora10,11, Kate Buchacz3,
1Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA. FFA2@cdc.gov.
2Cerner Corporation, Kansas City, MO, USA.
3Division of HIV Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
4Kansas University Medical Center, Kansas City, MO, USA.
5Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.
6Northwestern University Feinberg School of Medicine, Chicago, Illinios, USA.
7University of Illinois College of Medicine, Chicago, IL, USA.
8Vivent Health, Denver, CO, USA.
9University of Colorado Anschutz Medical Center, Aurora, CO, USA.
10AIDS Healthcare Foundation, Philadelphia, PA, USA.
11Colorado School of Mines, Golden, CO, USA.
Abstract
BACKGROUND: People with HIV (PWH) are more likely to smoke, have comorbidities, and be less likely to quit than the general population. This study aimed to describe the prescription of smoking cessation medications and quit smoking attempts, and to assess the effect of prevalent and incident comorbidity diagnoses on these two outcomes.
METHODS: We analyzed the 2007-2022 HIV Outpatient Study (HOPS…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans